Effectiveness of WHO HEARTS package in prevention and control of diabetes, hypertension, and hyperlipidemia in primary health care

Evaluation of the WHO HEARTS package to improve control of cardiometabolic risk factors in the primary health care system

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT20221126056612N1

Enrollment

1400

Registered

2022-12-05

Start date

2023-01-21

Completion date

Unknown

Last updated

2023-06-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Diabetes. Condition 2: Hypertension. Condition 3: Heart Disease. Condition 4: Hemorrhage Stroke. Condition 5: Hemorrhage Stroke. Condition 6: Ischemic Stroke. Diabetes mellitus due to underlying condition Essential (primary) hypertension Chronic ischemic heart disease Nontraumatic subarachnoid hemorrhage Nontraumatic intracerebral hemorrhage Cerebral infarction

Interventions

Intervention 1: Intervention group: Adopted WHO HEARTS technical package. The HEARTS technical package provides a strategic approach to improving cardiovascular health. It comprises six modules and an

Eligibility

Sex/Gender

All

Age

30 Years to No maximum

Inclusion criteria

Inclusion criteria: Adults aged 30 years or above Those with diabetes, hypertension, or hyperlipidemia or those with CVD/Diabetes risk of 10% or above

Exclusion criteria

Exclusion criteria: History of cardiovascular diseases Pregnancy Acute illness or medical emergency History of an Incurable disease

Design outcomes

Primary

Measure	Time frame
Hb A1c. Timepoint: 0,12 months. Method of measurement: Laboratory - enzymatic assay or using point of care.;Blood Pressure. Timepoint: 0, 12 months. Method of measurement: Mercury or digital sphygmomanometer.;Knowledge attitute and practice / Health literacy. Timepoint: 0, 12 months. Method of measurement: Validated questionnaires for Iranian population.;Patient satisfaction. Timepoint: 0 and 12 months. Method of measurement: Validated questionnaires for Iranian population.;Health System Staff satisfaction. Timepoint: 0 and 12 months. Method of measurement: Validated questionnaires for Iranian population.;Adherence to treatment. Timepoint: 0 and 12 months. Method of measurement: Validated questionnaires for Iranian population.;Fasting plasma glucose. Timepoint: 0 and 12 months. Method of measurement: Enzymatic lab measurements or using point of care.;Total Cholesterol. Timepoint: 0 and 12 months. Method of measurement: Enzymatic lab measurements or using point of care.;Cardiovascular risk score. Timepoint: 0 and 12 months. Method of measurement: CVD risk scoring model.;Diabetes risk score. Timepoint: 0 and 12 months. Method of measurement: Diabetes risk scoring model.	—

Measure

Time frame

Hb A1c. Timepoint: 0,12 months. Method of measurement: Laboratory - enzymatic assay or using point of care.;Blood Pressure. Timepoint: 0, 12 months. Method of measurement: Mercury or digital sphygmomanometer.;Knowledge attitute and practice / Health literacy. Timepoint: 0, 12 months. Method of measurement: Validated questionnaires for Iranian population.;Patient satisfaction. Timepoint: 0 and 12 months. Method of measurement: Validated questionnaires for Iranian population.;Health System Staff satisfaction. Timepoint: 0 and 12 months. Method of measurement: Validated questionnaires for Iranian population.;Adherence to treatment. Timepoint: 0 and 12 months. Method of measurement: Validated questionnaires for Iranian population.;Fasting plasma glucose. Timepoint: 0 and 12 months. Method of measurement: Enzymatic lab measurements or using point of care.;Total Cholesterol. Timepoint: 0 and 12 months. Method of measurement: Enzymatic lab measurements or using point of care.;Cardiovascular risk score. Timepoint: 0 and 12 months. Method of measurement: CVD risk scoring model.;Diabetes risk score. Timepoint: 0 and 12 months. Method of measurement: Diabetes risk scoring model.

—

Secondary

Measure	Time frame
Taking glucose lowering drugs. Timepoint: 0 and 12 months. Method of measurement: Checklist.;Taking blood pressure lowering drugs. Timepoint: 0 and 12 months. Method of measurement: Checklist.;Taking lipid drugs. Timepoint: 0 and 12 months. Method of measurement: checklist.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactLeila Molaeipour

Iran University of Medical Sciences

leilamolaei_epi@yahoo.com+98 21 2243 2500

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026